About Us

Our Team


Ronald Andrews

President and CEO

Ronnie Andrews joined Oncocyte as Chief Executive Officer in July 2019. Before joining Oncocyte, Ronnie was the founder and principal of the Bethesda Group LLC; a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms into the marketplace.

Ronnie has close to 30 years of experience in the US Clinical and Molecular Diagnostics industry. He served as the President of the Genetic Science Division for Thermo Fisher Scientific until December 2014. In this role, Ronnie oversaw the integration of Life Technologies’ genetic platforms, including Life’s chip-based Next Generation Sequencing Technology, Ion Torrent.

Before this, Ronnie held several other high-profile executive roles, including President of the Medical Sciences Venture within the Life Technologies Corporation, and he served as Chief Executive Officer of Clarient, a public company on the NASDAQ, which was sold to General Electric Healthcare in December 2010.

Ronnie is a passionate ambassador for the need for democratization of information into community-based environments to better manage deadly diseases like cancer, as well as control healthcare costs by keeping the patient and treatment close to home. He regularly speaks to industry groups and was selected as the Regional Winner for Ernst & Young’s Entrepreneur of the Year in 2011.

Mitch Levine

Chief Financial Officer

Mitch Levine joined Oncocyte as Chief Financial Officer in November 2017. Before joining Oncocyte, Mr. Levine was the Managing Partner of Kirby Cove Capital Advisors, which provides consulting services to international life sciences investment funds regarding collaboration and investment in US-based life sciences companies.

In 2002, Mr. Levine founded Enable Capital Management and grew the firm into one of the largest and most respected brands globally in alternative finance. Its flagship fund, Enable Growth Partners, provided growth capital to more than 500 private and publicly traded companies, catalyzing transformative corporate innovation, job growth, and economic expansion in technology, life sciences, consumer products, and energy.

Before founding Enable, Mr. Levine was a founding member of The Shemano Group, a leading San Francisco-based investment bank that focused on the capital needs of growth companies.

He has also worked at Bear Stearns and Lehman Brothers. Mr. Levine received his BA from the University of California, Davis.

Doug Ross M.D., Ph.D.

Chief Science Officer

Prior to joining Oncocyte, Dr. Doug Ross was a founding principal in the Bethesda Group, LLC, a boutique consulting firm that provided technical, commercial and operational expertise to the diagnostic and pharma industry. He is an experienced medical diagnostics R&D executive with a background in research and development at the intersections between genomics, proteomics and diagnostics. He co-founded a successful genomics-based diagnostic business, served in executive leadership positions in CLIA reference laboratories, and managed proprietary content through research, development and launch.

Doug’s private sector career started in 2000 as Chief Scientific Officer of Applied Genomics, Inc. (AGI), a company he co-founded coming out of post-doctoral training at Stanford University. AGI translated insights from gene expression patterns into immunohistochemistry multivariate assays targeted to actionable clinical problems.

In 2009, Clarient, Inc., a leading national pathology reference laboratory, acquired AGI. Doug continued his role as Chief Scientific Officer and launched two proprietary products. General Electric Healthcare acquired Clarient in December 2010, and Doug continued as CSO and worked closely with the business development and partnership teams at Clarient and capital teams at GE Healthcare.

In 2011 Doug joined the Medical Science Division of Life Technologies as CSO on a consulting basis until the acquisition of Life Tech by Thermo Fisher Scientific in 2013. He was CSO of CardioDx, Inc. from April to December of 2014. In September 2015, Doug became a founding principal in Bethesda Group, LLC.

Doug obtained his M.D. and his Ph.D. in Pathology from the University of Washington while studying at the Fred Hutchinson Cancer Research Center in Seattle, WA. He completed two years of Clinical Pathology training including serving as Chief Resident at the University of California at San Francisco before joining the genomics project as a post-doc with Patrick Brown at Stanford University in 1996.

Padma Sundar

Chief Commercial Officer

Padma Sundar has extensive experience in launching oncology tests for global diagnostics companies, helping them achieve market leadership positions.

Before joining Oncocyte, Ms. Sundar served as Vice President of Strategy and Market Access at CellMax Life, where she launched the first blood test for preventative colon cancer screening. Before CellMax, she was a Director of Marketing at Guardant Health, where she drove a 75% increase in test volume and adoption by U.S. oncologists.

As a Senior Director at Roche Sequencing, she launched the first next-generation sequencing (NGS) liquid biopsy kit for cancer recurrence monitoring. She was also Senior Director for the oncology portfolio at Affymetrix, where she brought the first whole-genome microarray kits “OncoScan” and “CytoScan” for solid and liquid tumor profiling to 50 leading academic and reference labs worldwide.

Ms. Sundar began her career at McKinsey and Company. She received her M.B.A. and M.P.H. from the University of California, Berkeley, and her B.A. in Chemistry from the University of Delhi.

Meet Our Scientific & Medical


David R. Gandara


David R. Gandara, MD, Professor of Medicine Emeritus at the University of California at Davis (UC Davis) School of Medicine, is the Senior Advisor to the Director, and Director of Thoracic Oncology at UC Davis Comprehensive Cancer Center (UCDCCC). He is an internationally known clinician-scientist, and lung cancer thought leader. He has led many notable research projects in lung cancer, including early therapeutics trials at various phases, cooperative group trials through the Southwest Oncology Group (SWOG), and multi-institutional translational science projects. He has been selected for many awards and honors, including the Lifetime Scientific Award from the International Association for the Study of Lung Cancer (IASLC) Dr. Gandara is the principal investigator for a National Cancer Institute (NCI) UG1 award to UCDCCC for Cancer Clinical Trials. He also is currently the principal investigator for UCDCCC for the Stand Up To Cancer (SU2C) dream team award in KRAS-mutated lung cancer and served as Clinical Director for the joint Jackson Laboratory (JAX)-UCDCCC patient-derived xenotransplant (PDX) program in lung cancer. He is past chair of the Southwest Oncology Group (SWOG) Lung Committee and is a founding co-chair and current member of the NCI-directed Investigational Drug Steering Committee (IDSC). He has written over 700 articles, book chapters, abstracts, and editorials. He is past editor-in-chief of the journal Clinical Lung Cancer. He served as president of the IASLC from 2009-2011 and served as treasurer from 2013-2017. He is a prior member of the board of directors and secretary-treasurer of the American Society for Clinical Oncology (ASCO). He consults for several pharmaceutical and cancer biomarker development companies.

Thomas Bauer


Dr. Bauer graduated from Jefferson Medical College and pursued his training in general surgery, research, and cardiothoracic surgery at Thomas Jefferson University Hospital. He served as the Chief of Thoracic Surgery at the Helen F Graham Cancer Center at Christiana Care Health System. Dr. Bauer currently serves as the Chief of Thoracic Surgery at Jersey Shore University Hospital. He is the Medical Director of Thoracic Oncology at Meridian Health in the Hackensack Meridian Health System. Dr. Bauer has led numerous clinical trials and has partnered with industry through device and pharmaceutical investigative trials for many years. He has authored over 100 manuscripts, chapters, abstracts, and presentations related to thoracic surgery. He has a particular interest in lung cancer screening research and clinical trials. His clinical expertise is in robotic minimally invasive thoracic surgery for the treatment of lung cancer, first rib resections, esophageal cancer, benign foregut surgery, and diaphragmatic pacing and reconstruction.

D. Kyle Hogarth


Dr. Hogarth is an Associate Professor of Medicine in the Section of Pulmonary and Critical Care Medicine at The University of Chicago. He is the Director of Bronchoscopy and is heavily involved in the field of interventional bronchoscopy with numerous publications. Dr. Hogarth received his medical degree at Case Western Reserve University School of Medicine in Cleveland, Ohio. He then completed a residency in Internal Medicine and a fellowship in Pulmonary and Critical Care at The University of Chicago. He is published in the New England Journal of Medicine, Chest, along with many other journals. He serves on the editorial board of CHEST, where he is the section editor for the podcast section.

Edward F. Patz Jr.


Dr. Patz is the James and Alice Chen Professor of Radiology and a Professor in Pharmacology and Cancer Biology at Duke University Medical Center. He began his training in High Energy Physics at Harvard University, received his MD from the University of Maryland, completed his residency and thoracic imaging fellowship at the Brigham and Women’s Hospital and Harvard Medical School, and then was appointed to the faculty in the Department of Radiology at the Brigham, Harvard Medical School, and the Dana Farber Cancer Institute. In 1991, he was recruited to the Thoracic Imaging section in the Department of Radiology at Duke. Dr. Patz is a clinician-scientist, with projects that focus on early lung cancer detection, molecular diagnostics, and novel therapeutic strategies. He has participated in numerous clinical trials, including the National Lung Screening Trial (NLST), and for over 20 years has been the principal investigator of a basic science laboratory exploring lung cancer biology.

Contact Us